{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:10:07Z","timestamp":1788448207422,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20290, 82170180,81800163, 82170182, 82020108003, 82100204, 82200211"],"award-info":[{"award-number":["U22A20290, 82170180,81800163, 82170182, 82020108003, 82100204, 82200211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D\u00a0Program\u00a0of\u00a0China","doi-asserted-by":"crossref","award":["2019YFC0840604"],"award-info":[{"award-number":["2019YFC0840604"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J06054, 2020J011246, 2021J011359,2020J05307"],"award-info":[{"award-number":["2023J06054, 2020J011246, 2021J011359,2020J05307"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010166","name":"Xiamen Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["3502Z20209003, 3502Z20224011, 3502Z20234001"],"award-info":[{"award-number":["3502Z20209003, 3502Z20224011, 3502Z20234001"]}],"id":[{"id":"10.13039\/100010166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key R&D Program of Jiangsu Province","award":["BE2019798"],"award-info":[{"award-number":["BE2019798"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Disease progression within 24 months (POD24) significantly impacts overall survival (OS) in patients with follicular lymphoma (FL). This study aimed to develop a robust predictive model, FLIPI-C, using a machine learning approach to identify FL patients at high risk of POD24.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cohort of 1,938 FL patients (FL1-3a) from seventeen centers nationwide in China was randomly divided into training and internal validation sets (2:1 ratio). XGBoost was utilized to construct the POD24-predicting model, which was internally validated in the validation set and externally validated in the GALLIUM cohort. Key predictors of POD24 included lymphocyte-to-monocyte ratio (LMR), lactate dehydrogenase (LDH)\u2009&gt;\u2009ULN, low hemoglobin (Hb), elevated beta-2 microglobulin (\u03b22-MG), maximum standardized uptake value (SUVmax), and lymph node involvement. The FLIPI-C model assigned 2 points to LMR and 1 point to each of the other variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The FLIPI-C model demonstrated superior accuracy (AUC) for predicting POD24 and 3-year overall survival (OS) in both the internal (AUC POD24: 0.764, OS: 0.700) and external validation cohorts (AUC POD24: 0.703, OS: 0.653), compared to existing models (FLIPI, FLIPI-2, PRIMA-PI, FLEX). Decision curve analysis confirmed the superior net benefits of FLIPI-C.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Developed using a machine learning approach, the FLIPI-C model offers superior predictive accuracy and utilizes simple, widely available markers. It holds promise for informing treatment decisions and prognostic assessments in clinical practice for FL patients at high risk of POD24.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40364-024-00716-4","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:22:06Z","timestamp":1735881726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma"],"prefix":"10.1186","volume":"13","author":[{"given":"Jie","family":"Zha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"issue":"2","key":"716_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.46883\/2022.25920946","volume":"36","author":"KE Cahill","year":"2022","unstructured":"Cahill KE, Smith SM. Follicular lymphoma: a focus on current and emerging therapies. Oncol (Williston Park). 2022;36(2):97\u2013106. https:\/\/doi.org\/10.46883\/2022.25920946.","journal-title":"Oncol (Williston Park)"},{"issue":"7","key":"716_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10(7):74. https:\/\/doi.org\/10.1038\/s41408-020-00340-z.","journal-title":"Blood Cancer J"},{"issue":"1","key":"716_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-021-01139-6","volume":"14","author":"J Zha","year":"2021","unstructured":"Zha J, Fan L, Yi S, et al. Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China. J Hematol Oncol. 2021;14(1):131. https:\/\/doi.org\/10.1186\/s13045-021-01139-6. Published 2021 Aug 23.","journal-title":"J Hematol Oncol."},{"issue":"7","key":"716_CR4","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00277-020-04025-2","volume":"99","author":"C Sortais","year":"2020","unstructured":"Sortais C, Lok A, Tessoulin B, et al. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. Ann Hematol. 2020;99(7):1595\u2013604. https:\/\/doi.org\/10.1007\/s00277-020-04025-2.","journal-title":"Ann Hematol"},{"issue":"23","key":"716_CR5","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516\u201322. https:\/\/doi.org\/10.1200\/JCO.2014.59.7534.","journal-title":"J Clin Oncol"},{"issue":"11","key":"716_CR6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo C, Dixon JG, Le-Rademacher J, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(11):1684\u201393. https:\/\/doi.org\/10.1182\/blood.2020010263.","journal-title":"Blood"},{"issue":"1","key":"716_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-023-00462-z","volume":"11","author":"J Zha","year":"2023","unstructured":"Zha J, Chen Q, Ye J, et al. Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1\u20132 follicular lymphoma: a real-world multicenter study. Biomark Res. 2023;11(1):16. https:\/\/doi.org\/10.1186\/s40364-023-00462-z. Published 2023 Feb 6.","journal-title":"Biomark Res"},{"issue":"12","key":"716_CR8","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/ajh.25973","volume":"95","author":"F Mir","year":"2020","unstructured":"Mir F, Mattiello F, Grigg A, et al. Follicular lymphoma evaluation index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy. Am J Hematol. 2020;95(12):1503\u201310. https:\/\/doi.org\/10.1002\/ajh.25973.","journal-title":"Am J Hematol"},{"issue":"9","key":"716_CR9","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1093\/annonc\/mdx189","volume":"28","author":"C Casulo","year":"2017","unstructured":"Casulo C, Nastoupil L, Fowler NH, Friedberg JW, Flowers CR. Unmet needs in the first-line treatment of follicular lymphoma. Ann Oncol. 2017;28(9):2094\u2013106. https:\/\/doi.org\/10.1093\/annonc\/mdx189.","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"716_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-142000","volume":"136","author":"W Wu","year":"2020","unstructured":"Wu W, Bruscaggin A, Valera A, et al. Evaluation of the different stratification models for POD24 prediction in patients with follicular lymphoma. Blood. 2020;136(Supplement 1):24\u20135. https:\/\/doi.org\/10.1182\/blood-2020-142000.","journal-title":"Blood"},{"issue":"5","key":"716_CR11","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258\u201365. https:\/\/doi.org\/10.1182\/blood-2003-12-4434.","journal-title":"Blood"},{"issue":"8","key":"716_CR12","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","volume":"128","author":"V Jurinovic","year":"2016","unstructured":"Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128(8):1112\u201320. https:\/\/doi.org\/10.1182\/blood-2016-05-717355.","journal-title":"Blood"},{"issue":"1","key":"716_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","volume":"132","author":"E Bachy","year":"2018","unstructured":"Bachy E, Maurer MJ, Habermann TM, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132(1):49\u201358. https:\/\/doi.org\/10.1182\/blood-2017-11-816405.","journal-title":"Blood"},{"issue":"9","key":"716_CR14","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111\u201322.","journal-title":"Lancet Oncol"},{"issue":"4","key":"716_CR15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","volume":"19","author":"S Huet","year":"2018","unstructured":"Huet S, Tesson B, Jais JP, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19(4):549\u201361. https:\/\/doi.org\/10.1016\/S1470-2045(18)30102-5.","journal-title":"Lancet Oncol"},{"key":"716_CR16","doi-asserted-by":"publisher","first-page":"e1915997","DOI":"10.1001\/jamanetworkopen.2019.15997","volume":"2","author":"RB Parikh","year":"2019","unstructured":"Parikh RB, Manz C, Chivers C, Regli SH, Braun J, Draugelis ME, Schuchter LM, Shulman LN, Navathe AS, Patel MS, et al. Machine learning approaches to predict 6-month mortality among patients with cancer. JAMA Netw Open. 2019;2:e1915997.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"716_CR17","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00259-021-05626-3","volume":"49","author":"FM de Jesus","year":"2022","unstructured":"de Jesus FM, Yin Y, Mantzorou-Kyriaki E, et al. Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [18F]FDG PET\/CT features. Eur J Nucl Med Mol Imaging. 2022;49(5):1535\u201343. https:\/\/doi.org\/10.1007\/s00259-021-05626-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"716_CR18","doi-asserted-by":"publisher","unstructured":"Hoang DT, Schalck E, Ricci R et al. Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM\/LYSA groups). Hematol Oncol, 41: 340\u2013340. https:\/\/doi.org\/10.1002\/hon.3164_243.","DOI":"10.1002\/hon.3164_243"},{"key":"716_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/hon.3165_533","volume":"41","author":"Y Liu","year":"2023","unstructured":"Liu Y, Chu Y, Zhan L, Lu T, Zhou X, Wang X. Development and validation of a machine learning model for predicting early progression\/relapse in follicular lymphoma. Hematol Oncol. 2023;41:681\u20132. https:\/\/doi.org\/10.1002\/hon.3165_533.","journal-title":"Hematol Oncol."},{"issue":"13","key":"716_CR20","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMp1606181","volume":"375","author":"Z Obermeyer","year":"2016","unstructured":"Obermeyer Z, Emanuel EJ. Predicting the Future - Big Data, Machine Learning, and Clinical Medicine. N Engl J Med. 2016;375(13):1216\u20139. https:\/\/doi.org\/10.1056\/NEJMp1606181.","journal-title":"N Engl J Med"},{"issue":"5","key":"716_CR21","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.3390\/ijerph18052679","volume":"18","author":"C Li","year":"2021","unstructured":"Li C, Patil V, Rasmussen KM, et al. Predicting Survival in Veterans with Follicular Lymphoma Using Structured Electronic Health Record Information and Machine Learning. Int J Environ Res Public Health. 2021;18(5):2679. https:\/\/doi.org\/10.3390\/ijerph18052679.","journal-title":"Int J Environ Res Public Health"},{"key":"716_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/cam4.1918","volume":"8","author":"F Lansigan","year":"2019","unstructured":"Lansigan F, Barak I, Pitcher B, et al. The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: a combined analysis of 3 CALGB trials. Cancer Med. 2019;8:165\u201373. https:\/\/doi.org\/10.1002\/cam4.1918.","journal-title":"Cancer Med"},{"issue":"3","key":"716_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ejh.13271","volume":"103","author":"R Dada","year":"2019","unstructured":"Dada R. Diagnosis and management of follicular lymphoma: a comprehensive review. Eur J Haematol. 2019;103(3):152\u201363. https:\/\/doi.org\/10.1111\/ejh.13271.","journal-title":"Eur J Haematol"},{"key":"716_CR24","volume-title":"NCCN clinical practice guidelines in oncology (NCCN Guidelines): B-cell lymphomas. Version 1","author":"National Comprehensive Cancer Network","year":"2023","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): B-cell lymphomas. Version 1. National Comprehensive Cancer Network; 2023."},{"key":"716_CR25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1614598.","journal-title":"N Engl J Med"},{"issue":"2","key":"716_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40487-021-00161-5","volume":"9","author":"TD Rodgers","year":"2021","unstructured":"Rodgers TD, Casulo C, Boissard F, Launonen A, Parreira J, Cartron G. Early Relapse in First-Line Follicular Lymphoma: a review of the clinical implications and available mitigation and management strategies. Oncol Ther. 2021;9(2):329\u201346. https:\/\/doi.org\/10.1007\/s40487-021-00161-5.","journal-title":"Oncol Ther"},{"key":"716_CR27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/annonc\/mds429","volume":"24","author":"AK Nooka","year":"2013","unstructured":"Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR. Examination of the follicular lymphoma inter- national prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. 2013;24:441\u20138. https:\/\/doi.org\/10.1093\/annonc\/mds429.","journal-title":"Ann Oncol"},{"key":"716_CR28","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3324\/haematol.11502","volume":"92","author":"M Federico","year":"2007","unstructured":"Federico M, Guglielmi C, Luminari F, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Haematologica. 2007;92:1482\u20138. https:\/\/doi.org\/10.3324\/haematol.11502.","journal-title":"Haematologica"},{"issue":"12","key":"716_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-019-0269-6","volume":"9","author":"G Yang","year":"2020","unstructured":"Yang G, Mills M, Kim Y, et al. Enhancement of the follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation. Blood Cancer J. 2020;9(12):104. https:\/\/doi.org\/10.1038\/s41408-019-0269-6. Published 2020 Jan 2.","journal-title":"Blood Cancer J"},{"issue":"6","key":"716_CR30","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","volume":"4","author":"A Davies","year":"2017","unstructured":"Davies A, Merli F, Mihaljevi\u0107 B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6):e272\u201382. https:\/\/doi.org\/10.1016\/S2352-3026(17)30078-9.","journal-title":"Lancet Haematol"},{"key":"716_CR31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature14539","volume":"521","author":"Y LeCun","year":"2015","unstructured":"LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521:436\u201344. https:\/\/doi.org\/10.1038\/nature14539.","journal-title":"Nature"},{"key":"716_CR32","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2147\/CMAR.S349193","volume":"14","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang Y, Wang W, Wei C, Zhao D, Zhang W. Follicular Lymphoma in China: systematic evaluation of follicular lymphoma prognostic models. Cancer Manag Res. 2022;14:1385\u201393. https:\/\/doi.org\/10.2147\/CMAR.S349193.","journal-title":"Cancer Manag Res"},{"key":"716_CR33","doi-asserted-by":"publisher","unstructured":"Mozas P, Ammar RO, Chartier L, Nastoupil L, Bachy E, Bezsera SM, Barnes J, Bijou F, Goy A, Zerazhi H, Cartron G, Ojeda-Uribe M, Choquet S, Joly B, Cheminant M, Garc\u00eda-Sancho AM, Eradat H, Gressin R, Abrisqueta P, Parcelier A, Salazar MJR, Bonnet C, Crump M, L\u00f3pez-Guillermo A, Morschhauser F. A low lymphocyte-to-monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial. Hematol Oncol. 41: 290\u20131. https:\/\/doi.org\/10.1002\/hon.3164_200.","DOI":"10.1002\/hon.3164_200"},{"issue":"22","key":"716_CR34","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","volume":"131","author":"AS Cottereau","year":"2018","unstructured":"Cottereau AS, Versari A, Luminari S, et al. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study. Blood. 2018;131(22):2449\u201353. https:\/\/doi.org\/10.1182\/blood-2017-11-816298.","journal-title":"Blood"},{"issue":"1","key":"716_CR35","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/S2352-3026(20)30365-3","volume":"8","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Trotman J. The role of PET in the first-line treatment of the most common subtypes of non-hodgkin lymphoma. Lancet Haematol. 2021;8(1):e80\u201393. https:\/\/doi.org\/10.1016\/S2352-3026(20)30365-3.","journal-title":"Lancet Haematol"},{"issue":"11","key":"716_CR36","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","volume":"19","author":"J Trotman","year":"2018","unstructured":"Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1530\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30618-1.","journal-title":"Lancet Oncol"},{"issue":"S2","key":"716_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/hon.75_2629","volume":"37","author":"J Leonard","year":"2019","unstructured":"Leonard J, Trneny M, Izutsu K, et al. AUGMENT phase III study: lenalidomide\/rituximab (R2) improved efficacy over rituximab\/placebo in relapsed\/refractory follicular patients irrespective of POD24 status. Hematol Oncol. 2019;37(S2):114\u20135.","journal-title":"Hematol Oncol"},{"issue":"6","key":"716_CR38","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","volume":"24","author":"C Casulo","year":"2018","unstructured":"Casulo C, Friedberg JW, Ahn KW, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transpl. 2018;24(6):1163\u201371.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"716_CR39","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1182\/blood.2021013437","volume":"139","author":"JP Leonard","year":"2022","unstructured":"Leonard JP. POD24 in follicular lymphoma: time to be wise. Blood. 2022;139(11):1609\u201310. https:\/\/doi.org\/10.1182\/blood.2021013437.","journal-title":"Blood"},{"issue":"6","key":"716_CR40","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/bloodadvances.2020003797","volume":"5","author":"E Bachy","year":"2021","unstructured":"Bachy E, Cerhan JR, Salles G. Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival. Blood Adv. 2021;5(6):1729\u201332.","journal-title":"Blood Adv"},{"key":"716_CR41","doi-asserted-by":"publisher","unstructured":"Townsend W, Hiddemann W, Buske C et al. Obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: final analysis of the GALLIUM study. HemaSphere. 2022;6:107-8. https:\/\/doi.org\/10.1097\/01.HS9.0000843716.68800.8b.","DOI":"10.1097\/01.HS9.0000843716.68800.8b"},{"issue":"6","key":"716_CR42","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","volume":"104","author":"JF Seymour","year":"2019","unstructured":"Seymour JF, Marcus R, Davies A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104(6):1202\u20138. https:\/\/doi.org\/10.3324\/haematol.2018.209015.","journal-title":"Haematologica"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-024-00716-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-024-00716-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-024-00716-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T07:15:27Z","timestamp":1735888527000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-024-00716-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["716"],"URL":"https:\/\/doi.org\/10.1186\/s40364-024-00716-4","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"9 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of all collaborative institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}